-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SEPnxyXn2FKSBIpRMI9TVutWeVqlw1aJ5P1CjV6Tki+5on7HSNKFxkAB1hEoqJnL nSq109NdBOGeBcb05vUwWg== 0000950103-05-002198.txt : 20051024 0000950103-05-002198.hdr.sgml : 20051024 20051024140211 ACCESSION NUMBER: 0000950103-05-002198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20051024 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20051024 DATE AS OF CHANGE: 20051024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 051151598 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 oct2405_8k.htm




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2005

Shire Pharmaceuticals Group plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)

0-29630		98-0359573
(Commission File Number)		(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code 44 1256 894 000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

	(c) Exhibits. The following exhibit is filed herewith:

99.01		Press Release dated October 24, 2005

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PHARMACEUTICALS GROUP PLC

By:	/s/ A C Russell

	Name:	Angus Russell
	Title:	Chief Financial Officer

Dated: October 24, 2005

EXHIBIT INDEX

Number		Description
99.01		Press Release dated October 24, 2005

EX-99.1 2 ex9901.htm

		EXHIBIT 99.01
	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com


	Press Release

THIRD QUARTER 2005 RESULTS DATE NOTIFICATION – November 3, 2005

Basingstoke, UK and Philadelphia, US – October 24, 2005 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce third quarter 2005 US GAAP earnings on Thursday, November 3, 2005.

	Results announcement time:	12:00 GMT / 07:00 ET
	Conference call time:	14:00 GMT / 09:00 ET

Live conference call:

Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call at 14:00 GMT/09:00 ET.

Please RSVP ssalah@uk.shire.com (T: +44 (0)1256 894 160).

The details of the live conference call are as follows:

	UK dial in	+44 (0) 1452 568 061
	US / Canada dial in	1866 224 2972
	Password	Shire

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations/Events section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks. Details are as follows:

	UK dial in	0845 245 5205
	US dial in	18662474222

	Stnd Int Dial In Number	+44 (0) 1452 55 00 00
	Pin code	1684507 #

	Webcast Replay	www.shire.com, in the investor relations section

Registered in England 2883758 Registered Office as above

If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160

For further information please contact:

Investor Relations	Souheil Salah (Rest of the World)	+44 1256 894 160

	Heidi Wunder (North America)	+1 484 595 8709

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetic therapies. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``_`*0#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`**^2_P!J+]NG]DW]C'1X=6_:0^-W@WX<7-]92W^C>%;FZGUGQYXAM8C+ M'Y^@>!-`@U3Q9JEFUQ"UHVIV^DG2;:Z*Q7E_;9+#\%O&/_!U=^RO8:MJ:_J'@7P8VIJTT<:3VFG6NL>+KR-98V9X8;P6MTTGEP20 M1&1GB^IR;@KBOB"E]8RC(\=B\/=*.)<(8?#3;;C:EB<5.A0JN+34U2J3&]%6(ABLAUJQTSQ+JGG*=GF6\GAF%`& M_=W+XS7V+\"?^"F/_!23]HKP&?C9\%_V&?V8OC+\,K>9'O\`PG\,OVX_!NL_ M%.QADA6X&DZDB^&;C0-!\4+!OF_L'7QINJL$$9TY"\;MZ6*\->,,!A_K69Y? MA,JH.HJ4*F9YSDV!C4JNW+3C+$8^"4I7]US<(-W2E=.V5+-\!7DX4*TJ\XQY MY1HT:]248W2U4:;=US:P5YJTO=O%I?T"T5^)WB+_`(+S_L6_#'X=_#/Q=\== M'^-7P@\6^/KCX@Z'K/PNUCX;ZEK/B_X>>-?A5XH'A#QYX0\7+IDHM[:^T[5W MM[C39U(75=%OK#4?)LY9I;*W^F/V)/\`@J=^R3_P4#\4>./!_P"SGKGC?5=; M^'N@:;XE\1Q>+/`VJ^$X(]*U347TNUDL[F_=X[N;[6FV6!"KHC+)@KG;Y&+X M/XGP.#Q&88O(\QHX#"SJ4Z^-EAY/"TY4J[PTW[>/-2E!5U[)5(2E3E+X)233 M.B&.P=2I&E#$T959I.-+VD54?-#VB7LVU-/D?-RM*26Z1^C-%%%?-G4%%?$/ M[;?_``4'_9P_X)]^&?`WBW]HW5?%FE:/\1-=U/P[X:D\*>$M0\63RZGI&GQ: MG>I>0:>Z-9PK:S(TJ>*_ M!_@V;QYK4'BKP'JOA2SC\/0:WH_A^26WO;]WBN+H:EKNGH+5`)#$\DH^6)J] MNGPWGU7*I9[2RG'5,G@IRGF,*$Y82,:=7V%1NJERI0JITY/9233V9SO%895O MJ[KTE7NE[%SBJEW%37N7YM8M2VVU/TLHHHKQ#H"BBB@`HHHH`****`"BBB@` MKX__`&W/VU_@O^PI\#O%/QB^+OB;0[&\L]"\13_#WP/>ZQ!IFO?%'Q?H^DRZ MA8^#O#,1BNKF2YOKDV=O?ZE'97-GH5K=KJ.I&.W4;_DG]N+_`(*>+\'O'T?[ M)7[(?@*7]IO]N;Q);QM8?#+127\*?#'3;F#S)?%GQ4\01SVUGI<.FPS6EXN@ MO>VDLJ7-K_:M_HZ7NFKJ7R7IG_!-+XW^#O@3\9_VT?VC;C2?VU?^"G@^%GB' MQ9\,-"^(-G9>+/A'\*/&6DZ7?:EX>\%_"3P/'O[0LIF6.RU&73[2SFU MR"U33M/TW3[B^@OOM\GX8PU-9=F/$V(C@,%CL1AHY?ECJPHYEF\*]2,(5WSZ M99D^K=?-\3%KV:E]3HXF;YH>=7QUK:.EAVHM\MMZU>VL:, M=$[>UE!-7_E3^-OPB^-7[0FL^)OVXO\`@HY\8+_X)CXM7::U\,O`FMZ#?>)? MCY\7/#=S.'T#0_@;\(+J_P##Z:)\*_#UG?V.AZ3XT\9:UX;\-VUM-!=Z;%XK MO)KD77[D_![_`(-R?&GB_P"%/@;6(?B1I'[(.NZCX?.I:G8R>$Y/C?\`'VYE M\10Q7'V/Q]\47\1_#WPUX0U/2+"1](N?"WP<\'>&=%07%Y::]K?C2XMK?5J_ MDG^*WQZ^-7QF^*$_Q:^,/Q`\5^//B;'J%K.WB#Q=>W%]J&G2:5=_:+#2[*TN M@+?1])TB=?)T_0+&VM-,TN%%L[2RMX(UB7^UC]D#_@YV_9M\=^&+#1OVNO"' MB+X+_$"QM[&UU#Q5X1T^?QC\/?$,XBV7NL)96QC\2>&/,G42#1TM/$B(DA*: MB`HA7^C^.:7B!E64Y7+A.C1J>QE5CC<)E>$PU:CEN'I4J%+`X3`8#$TI2QE! MQ=;VU:KA\1656G2J8>A@*;]FOB\KJY/7Q.(6.::VU74+& M&YTN*VG-ZGR7_P`$M/\`@H#XV_X)[_M1^$/B/9:QJ'_"G_%>JZ/X8^/O@Z%E MEL/$WP^FN9K>751:2GR_^$A\#MJ-QXF\-WL+072W%M=Z0UR-+UO5;>Z_T`;3 M]LC_`()L_P#!0#X:>+_@79_M"_"/XC>%OB_X9U7P3KG@74_$TW@CQ/K>G:Y; M?8KBVTK2/$Z^&O$JZI"]Q%)IU[H]O]MLM2BM[K3YTNH(I%^5)/\`@W/_`."6 M$B/&_P`&O&!21&1Q_P`+@^*`RK@JPR/%0(R"1D$'TKY#+_%2A_8F-R#Q/RK- MIXS$^VP]14\HHX9XG`U(12E5P]:K@HT<50K*;IU:%&,8RC1J0Y*U-R?H5.'F ML90QF2XBA"E3<)^]7E449QEJH2A&IS0G#XE*3O>4=F?@=_P<[^`]"\$?&#]F MJ[T2\DU-OB'HOQO^)NK:K)':1M?W_BWQMX=EM%06<%O"]KI7A^TT/0+"9T:Z MN-/TBUN+Z>YO9;BXD[;_`(-0O^3A/VL?^R->"_\`U-Y:;_P=3Z19>'_BK^Q7 MH.FI)'IVB?!CQSI&GQS32W$J66F^(_#MG:I+<3O)-/(L$,:O-,[RRL"\CL[$ MG\E/^"9W_!1[4/\`@G#IG[47C3P;X:@\2_%SXI_#KPMX"^&`U5!)X:\.ZK%X MAO-4U/Q;X@@#I)J,&AV21OI^C1M&FIZG<6JWGA\16VC^$-+AO,N=/M](BM;>4-MM8R&4'U[ M]B+_`(+5_MK?LE_%+PMKGBGXP?$/XX?!U-3@A\>?"?XC>*K_`,5VFJ>')V:. M_P#^$4U'Q%)J5YX1U^S60W^F7NCS6MO<7MM!:ZO!?Z;)<6LGYU6\!LY^HU,1 M@L]RK'XNG"3>$IPJTZ+%]O" ME6PN(H0FTE5J(_%&H7OB;1-2UJ'5(-;T*VTF&UM(]-O+-[>6"2!II))3( MKHP55!!-?.'_``1^_P""+GQ,_P"":_QW^)'Q<\;?&CP9\2=.\W/C+PEXF74I[G4=0NX9+9(/#D]J8$C60RW,4@<+&RMY!_P<'? MMH_%_P"&/[,'[&7QB_91^-?C[X9Z3\9_$.H^(H/$'@/Q!J?AB[\3^#-=^'NB M^*?#/]HMIUQ#)-;M;:E!>Q6\SNL,LS$?-DU\#?\`!#3]NC]L'X[_`!'_`&R] M-^,7[1OQ;^)-CX*_8G^*'CGPE9^,/&FM:Y;^'_&&E:[X2M]-\1:5%?74R6>K M6<-W558!VS.5Y7QM4\+\0Z.<9=A^'K8ZC6RFM@;Y@K9K.CB*; MQ#H.49RQ7--)U.:,'R7C9).K6RS_`%@IIT*TL.H_MJ_M"M8OJ>DF_^T_%#Q/Y#6INK M?[5YY-^P\DP[_-R&&PMD'D']*/\`@JK_`,%ZOCY\?/BIXL^%W[(_Q)\1?"#] MG;PEJ>I>'=.\5^!-1O?#WC3XN-9W2P2^+K[Q%!%8^(="\/7S03)H?AW3Y[%9 M])G%SKR75W<);6&%?P*XEI9C@<%3Q^7UZ&)IXJKB"4[*$5& M\I2:2NDDW9/_`$!J*_A<_P"""?\`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`8#$PR_),LJ_P3C<14JXFEEF%FZ=:I#V^)K1^*AA M8S47R?\`3VM)\D&VN17EORM?I[_P37_X)S^!?V"?A9=QW6I7'Q&_:"^)<\/B MKXX_&;Q$5U'Q-XF\5WUG:/J6CV&K7$9U"+PCI>H)=-I-E-,\T\MQA0Z M]:6&@Z[X2\6ZCIERL,ZM':&77M$L;$W1P#+=P6P.ZX56^?P]+-^->(J=&>)I MULVSC$.$:V+J>QH^T5.4H4KQA)4:484U1H4J<.2"5.E"*C9+JD\-EF#E)0=/ M#X:#DU!.4K7]Z3ZSDV^:4FVY.[;;/CO_`(*7?\&[7PN_:C\5^+OCI^S#XET[ MX)_&'Q*SZMK_`((N]-A_X51XS\0,,WFK-;:?#%J'A/7=;D`FU34M.:YTRYO6 MN=3N]$N=2O;J[D_E9_:'_P""-O\`P41_9JM)]7\:?L^>(O%7ARWDE1_$?PL; M_A85AB(C,G]GZ-%_PDJQ%2K"6304C&[E_E8C]=OV+_\`@X[_`&I_&W[4_P`# M_!7[2>H_#BP^"7C+QS8>$O'>IZ5X1T[2;O2+7Q)!E07K,K*"I_N+CDM[RWCFADANK6YB26*6-DGM[B"5`\C MVGC3P=XGOKSQ#K?@S1`SVMYKOPSN[^]232M2LHIQ>SZ(;A='US[-Y-U#%=M; MW]K_`'C?M9_L3?LO?M7?"OQAX*^.'PX\&W.G7V@ZEY7C0Z7INF>(O!EQ%;2S MQ>)](\0I##:-(OVX7+3B(1QRQW&8))5/^41J=K;V.IZE8V=_'JMG9:C? M6=IJD2&*+4[6UNI8+;4HHF^:.*_AC2[CC;YHTF5&Y!K]/X7XFR/Q8RC-L%F. M2>R6#^KTL5A\1*&)II8R-=T,1@L6J5*=*M"6&JNZA3J49*G*,IJ3:\''8+%\ M.8BA7P^+YXU'+E:3@WR@>._B'^PWX MW\*:E!K'A?QC\"_%_BGPWJ]JVZVU30?$&N^&M6TC4+=N\-Y87=O<1GKLD&>: M^9_^#;G]ECX=?M#_`+;?B?QI\3M"MO$^B_L^_#.;Q]X=T/44AN=(N/'VL^(- M+\,^'KW5]/GCDBU&WTC3;OQ%JEE!*IC@UNUTJ_(,MI#CY5_;XN_%][^PU_P2 M&G\:/6O/S*E6X<\(,UP>#Q4G4RREFF5T\73ERS MG3AQ%B"IU8W6SY9 M)-=+I']J7CCX;^!OB1X*U_X=^-O"^B^(?!GB;1[W0M9\/ZEIUK<:;=Z9?VTE MI/`;:2)HD_.O\H'_@HK_R M?Y^VM_V=5\?/_5H>)Z^&^C[B:_U[B3".I)X>6$P.(=-MN/MH5J]-5$GM)PJ2 MC)JW,E'FOR1MZO&,8^PP<^5<_M:D>:RYN7D3Y;VO:^MKVOK:Y^MW_!1'Q+JW MBS_@AM_P1YU;6[E[N^@N_B/X?2>1F9_[-\(_VQX3T6%F[>"P;]7_943^=FW(%O`2<`0QDD]`-B\FO[\O\`@B7_ M`,$>_P!G'P#^S%\*/VFOCA\.=&^*/QL^-_@O2OB!9Q>/=+M=9T3X>>$O%$9U M7PIIGAO0[^W:UM-5OO#<^E:GK6K7,,VJ?;;ZYT^&YCT^&*`?P"MQIK8_Y\3_ M`.B#7^P!\"((;7X'_!JVMXHX+>W^%/P[@@@B18XH88O"&CQQ11HH"I'&BJB( MH"JH```%>=X[9YF.59+E."R_%5L)'-<;BUBZN'J2I59T,%2HM8=U(-35.K4Q M49U(Q:YO8QC*\92B].%<+0KXO&5JM.-26'4/9*:4E&56=2\TGIS)4[)M.RD[ M6Z_QM?\`!SWKOPN^%^O?LZ?LU?";X?\`@_P%/K>CZK\;?B5+X3T#2M#EU^VM M+[5O`_PPM=3?38();J#2)C\4+B""Y#Q)+J*S1`2*QK\]O^"&GQD_8,_9K^._ MCO\`:"_;/\8?V-XB\$:'H^D_`O0[CPEJ/BG3FUKQ&=;C\8>,)5L;&]%KJWA[ M2[+2])T9I?+`3Q-JD\8>:")X?M7_`(.KOAIXATO]K+]G7XOS6[GPIXU_9]D^ M'FG787,:^(/AO\0_%OB'6;5V`^61M.^)^A31@GYU\S:/W;FOA'_@C;_P34^! M_P#P4J\2_'#P-\2/C#XM^&OC7X;Z-X-\3^$]#\+V^ASR^)_#>K7FOZ9XJU&1 M=8LKMF'AW48/"\#BU*[!K\;3`@H1W9"\HCX/X6IFF89CA\MQ.7REFN88"A1J5:4TL/0J., M*5J=#GC:_+&+7O58K3W]KMZ_UMZ]_P`%[/\`@DKXIT74O#?B7XQC7M`UBRN- M-U71=7^&/BG4-,U"PNX7M[FSN[*YT>2WGMYX)'BDCD1E9&92,&O\_P`_:OLO M@78_M(?&>#]F;5;C6O@#+XZU>^^%-Y=6U[:2Q^#]5:/5-/THP:FB7ZQZ";V7 M08VO$\^6/35E=I-_F/\`V'_\0IO[.?\`T+?A%HNM6*W<$=U:F\TS48[>]M? MM-K+#=0">&,RVTT,\8:*6-V^=X*S[PPX3Q&,>09UQ)C'C:-.-?"8C!XK%TOW M,TX8B-'#991E&K3]I*G[1MQ4*DXM-N+7;FF$SS,:=*.(PF$I.G/FA46(I1EK M&SC=S2LW[S6NJ5K6/VI_X(;?M#>)_P!I'_@FI\`?%'C:Z2_\6^`[;7_@UK%^ M&+S7]M\+]6F\.>%KV^Y/O%OCO3_';ZCX?U6VN;W6%TO1M2TW3[[PRJZ3 M-::==>'&B<1EYDOFO$G;>NQ"OY[XJJX&OQ)GM?+(RA@*^:8VMA:&/Q"953REF89O_!$+_@IE^RU MX<_8O^%?[+_QB\=6'P4^,?P,M=?\,:SH/Q!M[GPU9Z]8:CXR\2Z_I&L:+>7< M$<+2?V?JMO;:S;7AM[F#4XYI`)([A"G]+C*KJR.JNCJ5=&`965@0RLI!#*P) M!!!!!((Q7F%_\#_@OJMS+>:G\(OACJ-W.S//=7O@+PM=7$[N06>::?2GDE=B MH):1F;CK7O8?B[`U^$,/P?G.5XBMA\#F%3,-VX2494TFO9)OCJ9?5CF,\RPU:"J5*"P]6C6@W3G%.+4E.$E*$ER1 M^S/9K9V7$6O[6?[.6HP)/A5\,_^"@?[/WQE_9[\<>&_&&F?#OQII5MI%IXNU/1UTF6;5[6 MZCU?1?%?@V*^9[F63PUK>G:?>Q3WUK:+%?#0/4:!X>TC1@>,?\`,.L[;MQ].*ZFOEHXW#8+$4L5E4,;A\5AZU*OA<56 MQ5.53#U:-2%6G5A"CAZ*52,H:.4YQL[\MU<[_9SJ0E3Q#I5(3C*%2$8249QD MG%Q?-.3LTVFM/7H?Y1_[:G[`O[17["7Q5\0?#KXO^#]5;2M,N?.\-?$O2-.O MI_`_C#1)BKZ?K.F:TD+6MI/*K"*[TJ\FBOK"^BN;9DE2)+B7Z>_9Q_X+B_\` M!1#]F3P-I/PV\&?%NS\3>#=`L+?2]`TSXB^'=.\9SZ)IUH"EK8:=J6JK)>P6 M<$>(XH#*X5`!DX&/]*?QCX%\%_$/1;KPYX[\*>'O&&A7L$]MPUFQD MAN87@G`@OX)TC9XG9/-C"2J#E'5@"/RU\;?\$+O^"8_CC4[S5;C]G#1O#MU? MSRW-ROA'5=3T*W>:5P[NMO%--&F2"`J!54,P4#-?O>%\9N',ZP%+!<;\,1QM M2DH2=2AA\+CL+5K124J\<-BY4IX2<[7:I5*RU<4U"R/DY\-8S"UIU<=;*Z=VS^)O\`:2_X+??\%#?VG_`VM?#;QQ\7+/PY MX(\1Z?-I7B+1_A[X=T[P:^MZ9<#;=:?J>H:6L=Y<6-U'F.XM_,598R58XR#Y MS_P3G_X)E?'?_@H%\8/#GA;PYX;U[PO\(;2_T^^^)/Q;O]+N+70M!\*_:%:^ M30KN]A2TUOQ%?VT4]MH]C:&XB6[*2WK10(1)_=Y\/O\`@B#_`,$S?AUJ^GZY MIO[-7AO7=2TN:*YL9_%U[J/B!8KB$QM%*8+F=()61XUDQ+&Z%RQ9"&(K]1?# M?A;PSX.TFVT+PEX>T7PQHMFBQVNDZ!I=EI&G0(BA%$5G80P0*0J@%@FXXR23 MS6./\9E>$/AQ^SSXD\#>%M/W+FUT#PIJWA?0]*A=L*9 M94LK*'SYB-\TQ>60EW8GI_\`@U!96_:$_:QVLK8^#7@K."#C/C>7&<'C.#CZ M&O["/C/^RC^SA^T3J6A:Q\VM MD[NOE0W-Q;PS2J`=SQJ<\4?!G]E#]F_]G?4]:UGX'_!GP+\,-5\16%OIFN7_ M`(2T>/3+C5-/M+@W5M:7CH[>;##56CRZ-76J5CZ#K_)^_X**R1_\-^?MKC>F1^U7\?0?F7@CXH>)P0> M>H/!'8U_K`U\9^*O^">'[$'C?Q-XA\9^+?V8?A)X@\4^+-;U3Q'XDUW4O#,, M^H:SKNM7LVHZKJE],9`9;N_OKB>ZN),#?+*[8&:\?PSXYP/`^-S3%8[!8O&P MQ^%H4*<<)*C&5.5*M*HY3]M**::=ERN]UKH[KISS*JN:TJ%.E4ITW2J2FW4Y MK-2CRI+EC+\3^)O]NYE'_!"3_@C]EE&?$WQNQD@9_P"*D\7=,GGJ*G_X-V75 MOBI^WIM96(_X)]_&`_*03_R,?@KL,U_<;XC_`&,/V5?%WP[\#_"3Q-\!_AUK M?PT^&LNH3^`O!6H:''/H/A2;5I9I]2DT:S+[;5KR:XGDG*D[VE<\9I?A?^QC M^RM\%+WQ'J/PG^!'PZ\`WWB[PS?>#?$UUX;T..PFUOPMJ?IU MW-:6TDT!P&:%#GBOJ:OBOE53AC.:9OCZ5?VF&]E2IYEGM;-:<) MKGY^>G2JJE-Q3BZD;Q;B[KCI9#7IYCA,:ZU)PP^'H490M/FDZ6#6&DX^[:S: MYE=IVW5]#_)!>1/[-8;TS]A(QN&<^0>.M?[!'P/_`.2*_"#_`+)=\/\`_P!1 M/2:^9/\`AV-_P3]V[/\`ADGX+;=NW;_PBD&-N,8_UO3'%?<&GZ?9:586.EZ; M;16>G:;9VVGV%G`NR"TLK.%+>UMH4_@B@@CCBC7^%$`[5X_B=XBY=QU0R>E@ M,OQN">6UL?5JO%SH2518N&$C!0]C.33@\/+FYK)J4;=;=&29/6RN>*E5JTZB MQ'L[*GS7BZ;J-WYHK?VG3:W6^GY1?\%DO^">5S_P4/\`V4I?!7@^XL=.^,OP MPUX_$+X37VH92TU#4HK">PU_P=>SKAK>S\6Z1)]FBG),5KK5EHM[.DD-HZ'_ M`#Z?A1\2_P!K+_@FE^T=8>/-`TKQ-\&?C/X(?5]#NM)\8^'9H[74M/O8C9:Q MHVJ:7J,0T_Q!HMR!&Y\E[JR:YM[6[@F:2WC%? MCW\(?!7Q)TJ8Q,KZ_HUM+J=L]N28'M-8A6+4[?RBQ*QQW0AR?FC;BL^!/$W_ M`%9RZOP]G.6QSGA_$SJN5"]/VV'IXIU MD&:Y']>KT\9AJ[PN,I)6J).TW!ITVW%J490MRJ2O=635HJ_\0.O?\'/O[>FJ M>%[C1-*\'?!CPYKLMMY$7C"TT&^O[Z&7!5KE=)U"XDTCS&!+!1#LC<*4&`0? MS#^`G[/_`.UC_P`%6/VL3%!<>)?%GC7XL>+9]4^)7QAUNPU"Z\,>$[18&N-3 MUK7=2B1;*"'2M+M5MM(T*&XCN+CRK#3+.)(V$D?]Y5I_P0K_`."7]I=07)_9 MF\/72P2K*MG>:EJL]DVPY6.2#[2N^-<`!"_08)-?I9\+O@[\*_@EX7L?!7PD M^'_A3X>>%M.@CMK71O"NC6>E6PBB+F,3O;QK/>.AD?$UY-/,`Q'F8P*^KGXJ M\&Y!A<6^!^$_J.9XRG*G+%XFAAJ%*CI>G.7LZV*K8B-.HE46%O1H.<4W+H<3 MR',<94I/-F^%]'1@OVF\-I&9-0UC4'4`3:KKNJ2WNLZK<'YKC4+ZYF M/+T5[-17X!7KUL37K8G$5)UJ^(JU*U:M4DY5*M6K-SJ5)R>LISG)RDWJVVSZ 5R,8PC&,4HQBE&*6RBE9)>22LC__9 ` end -----END PRIVACY-ENHANCED MESSAGE-----